241 related articles for article (PubMed ID: 37787146)
21. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.
Mielke MM; Hagen CE; Xu J; Chai X; Vemuri P; Lowe VJ; Airey DC; Knopman DS; Roberts RO; Machulda MM; Jack CR; Petersen RC; Dage JL
Alzheimers Dement; 2018 Aug; 14(8):989-997. PubMed ID: 29626426
[TBL] [Abstract][Full Text] [Related]
22. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
[TBL] [Abstract][Full Text] [Related]
23. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Weigand SD; Figdore DJ; Lowe VJ; Vemuri P; Graff-Radford J; Ramanan VK; Knopman DS; Mielke MM; Machulda MM; Fields J; Schwarz CG; Cogswell PM; Senjem ML; Therneau TM; Petersen RC
Alzheimers Dement; 2024 Mar; 20(3):2143-2154. PubMed ID: 38265198
[TBL] [Abstract][Full Text] [Related]
24. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
26. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
27. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
[TBL] [Abstract][Full Text] [Related]
28. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
29. Association of Neurofilament Light Chain, [
Palleis C; Franzmeier N; Weidinger E; Bernhardt AM; Katzdobler S; Wall S; Ferschmann C; Harris S; Schmitt J; Schuster S; Gnörich J; Finze A; Biechele G; Lindner S; Albert NL; Bartenstein P; Sabri O; Barthel H; Rupprecht R; Nuscher B; Stephens AW; Rauchmann BS; Perneczky R; Haass C; Brendel M; Levin J; Höglinger GU
Neurology; 2024 Jan; 102(1):e207901. PubMed ID: 38165362
[TBL] [Abstract][Full Text] [Related]
30. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
31. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias.
Tsoy E; La Joie R; VandeVrede L; Rojas JC; Yballa C; Chan B; Lago AL; Rodriguez AM; Goode CA; Erlhoff SJ; Tee BL; Windon C; Lanata S; Kramer JH; Miller BL; Dilworth-Anderson P; Boxer AL; Rabinovici GD; Possin KL
Alzheimers Dement; 2024 Mar; 20(3):2089-2101. PubMed ID: 38224278
[TBL] [Abstract][Full Text] [Related]
32. Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic.
Bucci M; Bluma M; Savitcheva I; Ashton NJ; Chiotis K; Matton A; Kivipelto M; Di Molfetta G; Blennow K; Zetterberg H; Nordberg A
Transl Psychiatry; 2023 Jul; 13(1):268. PubMed ID: 37491358
[TBL] [Abstract][Full Text] [Related]
33. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
34. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Padilla C; Aranha MR; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Zetterberg H; Blennow K; Alcolea D; Clarimon J; Zaman SH; Blesa R; Lleó A; Fortea J
JAMA Neurol; 2021 Aug; 78(8):937-947. PubMed ID: 34228042
[TBL] [Abstract][Full Text] [Related]
35. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
Huang Y; Li Y; Xie F; Guo Q
CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
[TBL] [Abstract][Full Text] [Related]
36. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
[TBL] [Abstract][Full Text] [Related]
37. Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.
Chatterjee P; Doré V; Pedrini S; Krishnadas N; Thota R; Bourgeat P; Ikonomovic MD; Rainey-Smith SR; Burnham SC; Fowler C; Taddei K; Mulligan R; Ames D; Masters CL; Fripp J; Rowe CC; Martins RN; Villemagne VL;
J Alzheimers Dis; 2023; 92(2):615-628. PubMed ID: 36776057
[TBL] [Abstract][Full Text] [Related]
38. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
39. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
Asken BM; Elahi FM; La Joie R; Strom A; Staffaroni AM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Karydas A; Wang P; Rojas JC; Boxer AL; Miller BL; Rabinovici GD; Kramer JH; Casaletto KB
J Alzheimers Dis; 2020; 78(1):265-276. PubMed ID: 32986672
[TBL] [Abstract][Full Text] [Related]
40. Comparing tau status determined via plasma pTau181, pTau231 and [
Tissot C; Therriault J; Kunach P; L Benedet A; Pascoal TA; Ashton NJ; Karikari TK; Servaes S; Lussier FZ; Chamoun M; Tudorascu DL; Stevenson J; Rahmouni N; Poltronetti NM; Pallen V; Bezgin G; Kang MS; Mathotaarachchi SS; Wang YT; Fernandez Arias J; Ferreira PCL; Ferrari-Souza JP; Vanmechelen E; Blennow K; Zetterberg H; Gauthier S; Rosa-Neto P
EBioMedicine; 2022 Feb; 76():103837. PubMed ID: 35134647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
